Background: Intravitreal injections of bevacizumab have been reported to have anatomical and functional success in treating choroidal neovascularization, macular edema and neovascular glaucoma. We report a case with neovascular glaucoma due to central retinal vein occlusion who demonstrates rapid resolution of anterior and posterior segment neovascularization after a single intravitreal bevacizumab injection.
Case: A 46-year old man with a 6-month history of central retinal vein occlusion presented with neovascular glaucoma. Fluorescein angiography revealed marked leakage from new vessels on the iris, disc and retina. Bevacizumab was used after incomplete panretinal photocoagulation because of inadequate fundus visualization. About a week after intravitreal bevacizumab injection, new vessels were no longer visible. IOP improved and additional laser photocoagulation was performed.
Conclusion: Intravitreal bevacizumab injection may be a useful alternative or adjuvant treatment for patients with neovascular glaucoma in whom inadequate visualization precludes adequate panretinal photocoagulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-007-9105-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malignant Transformation of a Choroidal Nevus.
Cureus
December 2024
Department of Ophthalmology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, CHN.
Choroidal nevus is the most common intraocular tumor, and most cases are benign and have no symptoms. However, choroidal nevus carries a low risk for transformation into melanoma, which is a highly aggressive and deadly cancer. In this case report, we present a male patient with blurred vision in his left eye for six months.
View Article and Find Full Text PDFSimple reaction time to visual and auditory stimulation in glaucoma.
Eur J Ophthalmol
January 2025
University of Lille, Inserm, CHU Lille, UMR-S 1172 - Lille Neurosciences and Cognition, CNRS, 59000 Lille, France.
Background/objectives: Glaucoma can impact the ability to perform daily life activities such as driving. In such tasks, reaction time is critical to detect hazards. Understanding the modalities that affect response times is thus essential for clinical care.
View Article and Find Full Text PDFProfile and outcomes of retinal artery occlusion: The underrealized need to expedite presentation.
Indian J Ophthalmol
January 2025
Indian Health Outcomes, Public Health, and Economics Research Center, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.
Purpose: To evaluate the clinical profile of retinal artery occlusion (RAO) and impact of presentation on visual outcomes.
Design: A retrospective analysis of case files of 3070 patients with RAO was performed using electronic medical records.
Methods: Demographic data were analyzed using descriptive statistics.
The Association of Primary Open Angle Glaucoma and Ocular Hypertension with Anti-VEGF Injections.
Clin Ophthalmol
December 2024
Department of Ophthalmology, Acuity Eye Group, Pasadena, CA, USA.
Purpose: To study the effects of anti-VEGF injections on the prevalence of ocular hypertension (OHT), sustained elevated intraocular pressure (SE-IOP), and primary open-angle glaucoma (POAG) with age-matched controls.
Methods: A retrospective case-control study was performed with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME) against a control group involving atrophic AMD or diabetic retinopathy (DR) without DME. Bevacizumab, ranibizumab, or a combination of both were used in the treatment group.
Evaluation of Sustained Intraocular Pressure Elevations Across Antivascular Endothelial Growth Factor Agents.
J Vitreoretin Dis
December 2024
Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA.
To evaluate the effect of antivascular endothelial growth factor (anti-VEGF) agents on the development of sustained intraocular pressure (IOP) elevations. This single-center retrospective cohort study included eyes receiving anti-VEGF injections for various indications along with nontreated fellow eyes from 2012 to 2022. Patients were grouped according to treatment with bevacizumab, ranibizumab, or aflibercept.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!